Annales d'endocrinologie最新文献

{"title":"Diabetes in deprived patients.","authors":"Aurélie Bérot, Thi-Lan Huong Do, Hélène Bihan","doi":"10.1016/j.ando.2026.102601","DOIUrl":"10.1016/j.ando.2026.102601","url":null,"abstract":"<p><p>Low educational level and living in a disadvantaged area are two factors that increase the risk of developing type-2 diabetes (T2D) by 20-50%. For type-1 diabetes (T1D), there is no such socioeconomic gradient. For the most deprived patients with T2D, many studies confirmed associations between socioeconomic deprivation and poorer health behavior, lower compliance with follow-up examination and higher HbA1c levels, which probably contribute to an increased risk of complications and even mortality. The gradient is even higher for women. For patients with T1D, deprivation also increases the risk of complications and diabetes-related mortality. The issue of equal access to new technologies must be considered by healthcare teams. In practice, screening for deprivation and assessing health literacy levels are the first diagnostic steps, in order to involve other stakeholders such as social workers and health mediators, and to develop patient partnerships.</p>","PeriodicalId":93871,"journal":{"name":"Annales d'endocrinologie","volume":" ","pages":"102601"},"PeriodicalIF":2.9,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rebuilding beta-cell function: Advances in replacement, preservation and regeneration.","authors":"Valentin Lericque, Gianni Pasquetti, Julien Thevenet, Omolara Tijani, Priya Gnanasekar, Arnaud Jannin, Valéry Gmyr, Julie Kerr-Conte, Marie-Christine Vantyghem","doi":"10.1016/j.ando.2026.102591","DOIUrl":"10.1016/j.ando.2026.102591","url":null,"abstract":"<p><p>Since the life-saving discovery of insulin in 1921, multiple approaches have been developed to improve long-term outcomes in patients with type 1 diabetes (T1D). While technological advance such as closed-loop insulin delivery systems are now well known to most endocrinologists, biological approaches to restore beta-cell mass remain less widely recognized but are rapidly evolving. Since 2021, islet transplantation has been covered by the French national health insurance system. Nevertheless, islet allotransplantation requires complex isolation procedures from brain-dead donors, limiting access to a sufficient islet mass and requiring lifelong immunosuppression. Therefore, alternative strategies have been developed to restore the beta-cell pool: preservation of residual beta cells, or regeneration. A major advance in beta-cell preservation was the marketing authorization of teplizumab by the FDA (2022) and the European Medicine Agency (2025). This anti-CD3 monoclonal antibody has been shown to delay the onset of clinical T1D in individuals with stage 2 disease. Beta-cell regeneration encompasses several approaches: differentiation from stem cells, proliferation of existing beta cells, dedifferentiation, neogenesis from ductal cells, and transdifferentiation of endocrine, exocrine or extra-pancreatic cells. Three of these pathways led to major breakthroughs in 2025. Firstly, insulin independence under immunosuppression was achieved at 1 year in 83% of patients after intraportal transplantation of human embryonic stem-cell-derived islets. Secondly, insulin independence was reported in China in individual cases following transplantation of autologous chemically induced pluripotent stem-cell-derived islets or allogeneic stem-cell-derived islets. And thirdly, stable human C-peptide production was observed 12 months after intramuscular transplantation of engineered hypoimmune islets without immunosuppression. The present review summarizes these recent advances, from experimental models to clinical applications, opening up new perspectives for cell-based therapies in T1D.</p>","PeriodicalId":93871,"journal":{"name":"Annales d'endocrinologie","volume":" ","pages":"102591"},"PeriodicalIF":2.9,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of glycemic control with automated insulin delivery in adults living with type 1 diabetes: A 12-month sub-analysis of the French OB2F Registry.","authors":"Michael Joubert, Jean-Baptiste Julla, Eric Renard, Sandrine Lablanche, Agnès Sola, Emmanuel Cosson, Jean-Paul Donnet, Emmanuel Sonnet, Anne Vambergue, Salah Fendri, Lucien Marchand, Amal Lemoine, Laurence Kessler, Mathieu Giraud, Isabela Banu, Elise Pinto Da Rocha, Camille Vatier, Françoise Plat, Aurélie Carlier, Jean-François Gautier, Jean-Pierre Riveline","doi":"10.1016/j.ando.2026.102600","DOIUrl":"10.1016/j.ando.2026.102600","url":null,"abstract":"<p><strong>Objective: </strong>To identify baseline determinants of achieving international continuous glucose monitoring (CGM) targets after 12 months of automated insulin delivery (AID) in adults with type 1 diabetes.</p><p><strong>Research design and methods: </strong>This predefined sub-analysis of the nationwide French OB2F registry included adults with type 1 diabetes initiating MiniMed 780G or Tandem Control-IQ in 2022. Participants required ≥14 consecutive days of CGM data at baseline and 12 months. The primary outcome was achievement of combined CGM targets at 12 months, defined as TIR >70% and TBR <4%. Baseline predictors were assessed using multivariable logistic regression.</p><p><strong>Results: </strong>Among 1,058 adults, 43% achieved combined CGM targets at 12 months (52% of MiniMed 780G users and 36% of Tandem Control-IQ users). Better baseline metabolic control, including higher TIR and lower HbA1c, TAR, GMI, and glucose variability, was independently associated with target achievement across both systems. Lower baseline TBR predicted target achievement only in MiniMed 780G users. GRI improved in both systems, from 44.1±19.4 to 30.2±13.6 with MiniMed 780G and from 49.4±20.0 to 36.7±14.9 with Tandem Control-IQ.</p><p><strong>Conclusions: </strong>Baseline glycaemic profile is the main determinant of achieving international CGM targets after AID initiation in adults with type 1 diabetes, despite substantial improvement in those with poorer baseline control.</p>","PeriodicalId":93871,"journal":{"name":"Annales d'endocrinologie","volume":" ","pages":"102600"},"PeriodicalIF":2.9,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148498450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The tip of the iceberg: Morbidity in polycystic ovary syndrome in reproductive-age women.","authors":"Blandine Courbiere, Eugénie Micolon, Appoline Zimmermann, Pascal Auquier, Julie Berbis, Sandrine Loubière","doi":"10.1016/j.ando.2026.102598","DOIUrl":"10.1016/j.ando.2026.102598","url":null,"abstract":"<p><strong>Context: </strong>Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women, but its true burden remains underestimated due to diagnostic variability and underreporting.</p><p><strong>Objective: </strong>To estimate the morbidities in reproductive-age women identified with a diagnosis of PCOS in the French national health data system.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the French national health data system (SNDS) to identify reproductive-age women (18-43 years) diagnosed with PCOS (ICD-10 code E28.2) between 2014 and 2022. Morbidity data were assessed in 2022 and compared with an age-matched control group of women without PCOS in the same year. Specific comorbidities were identified using a set of algorithms applied to the system's data and based on both ICD-10 codes and medical acts and drug use. Logistic regression models were used to compare comorbidity rates, with odds ratios adjusted for age and social deprivation.</p><p><strong>Results: </strong>We identified 21,144 women with PCOS in the health data system. Median age was 35 years [IQR: 29-39]. Compared with the general female population, women with PCOS had significantly higher rates of infertility (adjusted odds ratio (aOR)=24.35), gestational diabetes (aOR=1.64), type 2 diabetes (aOR 14.71), pulmonary embolism (aOR=2.04), arterial hypertension (aOR 5.86), acute stroke (aOR= 2.39), cardioneurovascular disease (aOR 2.12) and psychiatric disorders (aOR=1.66).</p><p><strong>Conclusions: </strong>Given the high morbidity among women identified with PCOS on ICD-10 code E28.2, improved diagnostic algorithms are needed to better identify PCOS cases in health databases and assess their public health implications.</p>","PeriodicalId":93871,"journal":{"name":"Annales d'endocrinologie","volume":" ","pages":"102598"},"PeriodicalIF":2.9,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148458062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoperative location of parathyroid glands during total thyroidectomy: a systematic review of the literature according to the PRISMA method.","authors":"A Vialle, C Maheo, J C Leclere, R Marianowski","doi":"10.1016/j.ando.2026.102585","DOIUrl":"https://doi.org/10.1016/j.ando.2026.102585","url":null,"abstract":"<p><p>Postoperative hypocalcemia is one of the most common complications of total thyroidectomy. Permanent hypocalcemia occurs in 1-3% of total thyroidectomies and has a major impact on quality of life and on medico-economic aspects. The present systematic review of the literature, using the PRISMA methodology, included 169 interventional studies, from 1969 to 2025, evaluating intraoperative parathyroid location methods during total thyroidectomy and their impact on postoperative serum calcium levels. Despite the large number of studies published on the subject, only six reported reduction in the incidence of permanent hypocalcemia using carbon nanoparticles, indocyanine green angiography or autofluorescence. Nanoparticles show promise in reducing the incidence of permanent hypocalcemia, and is the most widely used method to assess postoperative hypocalcemia. It also limits the number of accidental parathyroidectomies and autotransplantations, and three of the six studies showed a decrease in the frequency of permanent hypocalcemia. To date, no prospective randomized controlled studies have shown a decrease in the frequency of permanent postoperative hypocalcemia. Studies showing these results were retrospective and controlled, covering the period from 2019 to 2024. Improving intraoperative location of the parathyroid glands during total thyroidectomy is a public health issue, to reduce the incidence of hypocalcemia.</p>","PeriodicalId":93871,"journal":{"name":"Annales d'endocrinologie","volume":" ","pages":"102585"},"PeriodicalIF":2.9,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148341548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Paris, France, 20-21 May 2025.","authors":"Camille Vatier, David Araújo-Vilar, Baris Akinci, Thierry Arnould, Carine Beaupère, Elise Bismuth, Rebecca J Brown, Giovanni Ceccarini, Philippe Collas, Alessandra Gambineri, Donatella Gilio, Sharon Halperin, Sonja Janmaat, Sophie Lamothe, Giovanna Lattanzi, Margherita Maffei, Ormond A MacDougald, Héléna Mosbah, Estelle Nobecourt, Elif A Oral, Justin Rochford, Ferruccio Santini, Eric C Schirmer, Julia von Schnurbein, Robert Semple, Daniel Tews, Martin Wabitsch, Marie-Christine Vantyghem, Corinne Vigouroux","doi":"10.1016/j.ando.2025.102432","DOIUrl":"10.1016/j.ando.2025.102432","url":null,"abstract":"<p><p>Lipodystrophy syndromes are rare diseases characterized by anatomical and functional defects of adipose tissue, frequently leading to severe insulin resistance-associated metabolic complications. Subtypes of lipodystrophy syndromes differ in: their clinical presentation, with generalized or partial loss of adipose tissue; in their origin, either genetic or acquired; and in their comorbidities, forming a heterogeneous group of disorders of different severity. The European Consortium of Lipodystrophies (ECLip) was founded in 2014 as a non-profit network of health professionals, scientists and patient associations. ECLip aims to promote international collaborations to increase pathophysiological and clinical knowledge, and improve the management of lipodystrophy syndromes. ECLip now comprises 59 groups from 30 countries from Europe and beyond. The consortium developed in parallel to the increased awareness of clinical diagnosis, the growing scientific interest for these diseases at the crossroads between adipose tissue biology, whole body metabolism, genetics and immunity, and to the emergence of new pharmacological approaches. The ECLip congress, held every 18 months, aims to discuss the recent achievements and projects in the field of lipodystrophies, to consolidate ECLip activities and to promote future collaborations, highlighting clinical and fundamental aspects as well as patients' perspectives. Oral communications presented during the meeting in Paris, France, in 2025 are summarized in these minutes.</p>","PeriodicalId":93871,"journal":{"name":"Annales d'endocrinologie","volume":" ","pages":"102432"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144765811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"20-Hydroxyecdysone induces brown adipose tissue glycogen accumulation in obese gerbil model: Histochemical study","authors":"Z. Bellahreche, O. Sihali-Beloui, N. Semiane, A. Mallek, Y. Dahmani","doi":"10.1016/j.ando.2023.07.469","DOIUrl":"https://doi.org/10.1016/j.ando.2023.07.469","url":null,"abstract":"Obesity is a major public health problem. It is defined as an abnormal or excessive accumulation of fat harmful to health. Although the majority of obesity studies focus on changes in white adipose tissue, investigations into brown adipose tissue and its activation are becoming an increasingly popular area of interest. In this study, we attempted to examine the effects of 20-hydroxyecdysone (20E) on the glycogen amount stored in interscapular brown adipose tissue (IBAT). 15 gerbils were divided into: control group submitted to natural diet, two experimental groups submitted to high-calorie-diet supplemented or not with 20E. At the end of the experimental period, the animals were sacrificed and the IBAT was fixed in 10% formalin. Sections of 5 micrometers were made and stained with periodic acid-Schiff (PAS), to highlight the polysaccharides. Glycogen quantification in IBAT was performed using ImageJ software (NIH, Bethesda, MD, USA). PAS staining demonstrated that in the control gerbils, IBAT had strong cytoplasmic presence of glycogen. However, in the high-calorie diet group, the microscopy images had weaker PAS staining with lipid droplets infiltration compared to control group. We observed an important IBAT cytoplasm staining with PAS in group treated with 20E, indicating cells glycogen overload with reduction of lipid droplets accumulation. The quantification of glycogen had confirmed the qualitative study. Although the relationship between brown adipose tissue and glycogen storage remains underestimated and misunderstood, these preliminary results show that 20E could activate obese gerbil's brown adipocytes to store more glycogen.","PeriodicalId":93871,"journal":{"name":"Annales d'endocrinologie","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135274371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L’hémiballisme secondaire à l’hyperglycémie non cétosique : une situation rare","authors":"Z. Habbadi, I. Gam","doi":"10.1016/j.ando.2023.07.455","DOIUrl":"https://doi.org/10.1016/j.ando.2023.07.455","url":null,"abstract":"Le diabète déséquilibré peut entraîner des complications neurologiques comme des crises épileptiques et des troubles de conscience. L’hémiballisme est une manifestation plus rare. Le mécanisme expliquant la survenue de ces mouvements anormaux lors d’une hyperglycémie sans cétose reste mal élucidé. Patiente de 67 ans, hypertendue sous traitement, diabétique de type 2 depuis 4 ans sous association metformine et insuline. Admise aux urgences neurologiques pour des mouvements anormaux de l’hémicorps droit d’apparition brutale. Ces mouvements prédominent au niveau proximal, d’abord au niveau du membre supérieur droit, puis au membre inférieur homolatéral à type de flexion extension et de rotation. Ils sont brusques et irréguliers altérant sa qualité de vie. Le bilan étiologique révèle une hyperglycémie à 5 g/L sans hyperosmolarité ni cétonurie ni syndrome infectieux associé. La TDM cérébrale montre une atteinte du striatum gauche. L’évolution était marquée par la disparition de l’hémiballisme deux semaines après l’équilibre glycémique et la mise sous neuroleptique à faible dose. L’hémiballisme est un mouvement unilatéral rapide, brutal, non rythmique, non suppressible, dû à une atteinte du striatum controlatéral. Bien que rare, l’hyperglycémie non cétosique est l’une de ses causes. Dans ce cadre, plusieurs hypothèses sont avancées. En effet, l’épuisement de l’acide gamma-aminobutyrique et de l’acétate au cours de l’hyperglycémie sans cétose, avec le manque d’énergie et l’acidose métabolique, serait à l’origine de l’apparition des mouvements anormaux. Le diagnostic est radiologique et le traitement repose sur l’équilibre glycémique.","PeriodicalId":93871,"journal":{"name":"Annales d'endocrinologie","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135274381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiothyréose : à propos de neuf cas","authors":"W. Ben Hilel, I. Rojbi, S. Mekni, S. Essayeh, K. Khiari, I. Ben Nacef","doi":"10.1016/j.ando.2023.07.254","DOIUrl":"https://doi.org/10.1016/j.ando.2023.07.254","url":null,"abstract":"La cardiothyréose, complication majeure de l’hyperthyroïdie peut révéler ou survenir après le diagnostic la maladie. L’objectif de ce travail est de décrire le profil clinique, paraclinique et évolutif de la cardiothyréose. Il s’agissait d’une étude rétrospective descriptive réalisée à partir des patients hyperthyroïdiens hospitalisés dans notre service entre 2008 et 2022. Le diagnostic de cardiothyréose était retenu devant un trouble de rythme, une insuffisance cardiaque ou coronaire. Au total, 4 % des patients hyperthyroïdiens avaient une cardiothyréose (9/227). L’âge moyen était 55 ± 12 ans avec un sexe ratio = 2. La fréquence cardiaque moyenne était à 166 ± 32. L’amaigrissement et les palpitations étaient les signes prédominants retrouvés chez huit patients. L’hyperthyroïdie était fruste chez un patient. Le taux moyen de TSH était à 0,032 ± 0,02 U/ml et de FT4 à 3,5 ± 1,96 ng/dl [VN : 0,7–1,48]. Huit patients avaient une maladie de Basedow. L’arythmie cardiaque par fibrillation atriale (ACFA) était objectivée chez tous les patients et révélatrice de l’hyperthyroïdie dans trois cas. L’association ACFA et insuffisance cardiaque étaient présente chez deux patients. L’ETT montrait Une FEVG inférieure à 50 % et une HTAP dans deux cas. Le bisoprolol a été prescrit chez cinq patients. Parmi les six patients suivis après normalisation de la FT4, on obtenait la conversion de l’ACFA chez trois. La cardiothyréose est une complication sérieuse de l’hyperthyroïdie pouvant menacer le pronostic vital. L’ACFA est la forme clinique la plus fréquente et le retour au rythme sinusal n’est pas constant après contrôle de l’hyperthyroïdie, d’où l’intérêt du diagnostic et de prise en charge précoce de l’hyperthyroïdie.","PeriodicalId":93871,"journal":{"name":"Annales d'endocrinologie","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135274386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospitalisations pour maladies hypophysaires : profil épidémiologique et évolutif sur 13 ans","authors":"M. Baklouti, H. Ben Ayed, N. Hentati, O. Laajili, M. Trigui, F. Hadj Kacem, G. Nasri, R. Karray, J. Jdidi, S. Yaich, J. Dammak","doi":"10.1016/j.ando.2023.07.178","DOIUrl":"https://doi.org/10.1016/j.ando.2023.07.178","url":null,"abstract":"Les maladies hypophysaires (MH) constituent un des motifs les plus répondus en endocrinologie, dont la prise en charge pourrait parfois nécessiter l’hospitalisation. L’objectif de cette étude était de dresser le profil épidémiologique et évolutif des hospitalisations pour MH sur une période de 13 ans. Il s’agissait d’une étude rétrospective ayant inclus les patients hospitalisés pour MH dans le CHU Hedi Chaker Sfax, Tunisie, durant la période 2006–2018. Sur un total de 148 596 admissions, 240 patients (0,16 %) étaient hospitalisés pour MH. Le sexe ratio était de 0,55. L’âge médian était de 43 ans (Intervalle interquartile (IIQ) = [30,7–53] ans). Ils y avaient 39 patients (16,3 %) âgés de plus de 60 ans. 158 patients (65,8 %) étaient hospitalisés pour une insuffisance hypophysaire et 82 cas (34,2 %) étaient admis pour un hyperaldostéronisme. La durée médiane du séjour était de 7 jours (IIQ = [5–10]). Une durée > 7 jours était notée chez 119 patients (49,6 %). Au total, 14 patients (5,8 %) présentaient des comorbidités associés, dont 5 (2 %) étaient endocriniennes. Le taux de létalité était de 0,4 %. L’étude des tendances chronologiques a montré une allure globale significativement à la baisse (Rho = (–0,83) ; p < 0,001)), de même que pour insuffisance hypophysaire (Rho = (–0,8) ; p = 0,001) et pour hyperaldostéronisme (Rho = (–0,73) ; p = 0,003). Malgré leurs tendances chronologiques à la baisse, les MH continuent à être une source de morbidité en milieu de soins, notamment chez les adultes jeunes. Une prise en charge adéquate et continue de ces maladies est primordiale pour prévenir les formes graves.","PeriodicalId":93871,"journal":{"name":"Annales d'endocrinologie","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135274403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}